Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nephrotoxicity Biomarker Prepares For Clinic After FDA Blesses Animal Test

Executive Summary

The firms that obtained FDA/EMEA qualification of seven nephrotoxicity biomarkers for preclinical drug testing are midway through development of a protocol to test their efficacy in a clinical trial

You may also be interested in...



Drug Development Tools: Passed And Future

FDA has qualified a total of eight biomarkers submitted by two different consortia through a process that has followed, to varying degrees, the route described in the recently released draft guidance on drug development tool qualification.

BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development

BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.

BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development

BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.

Related Content

UsernamePublicRestriction

Register

PS049702

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel